Enhancement of vaccine-induced primary and memory CD8+ t-cell responses by soluble PD-1

Journal of Immunotherapy

Volumn 34, Issue 3, 2011, Pages 297-306

  Song, Mi Young ^a   Park, Sang Hoon ^a   Nam, Hyo Jung ^a   Choi, Dong Hoon ^a   Sung, Young Chul ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

adjuvant; PD 1; T cell priming; vaccination

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL XL; PROTEIN E7; WART VIRUS VACCINE;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIVISION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DNA IMMUNIZATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TISSUE LEVEL; EMBRYO; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; DENDRITIC CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PAPILLOMA; PAPILLOMAVIRUS E7 PROTEINS; VACCINES, DNA;

EID: 79953063507     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318210ed0e     Document Type: Article

References (44)

1. Faurez F, Dory D, Le Moigne V, et al. Biosafety of DNA vaccines: new generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine. 2010;28: 3888-3895.
2. Coban C, Koyama S, Takeshita F, et al. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin. 2008; 4:453-456.
3. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 2006;12: 216-222. (Pubitemid 43728411)
4. Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538-5545. (Pubitemid 35291652)
5. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. (Pubitemid 351600389)
6. Hokey DA, Johnson FB, Smith J, et al. Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol. 2008;38: 1435-1445.
7. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239-245. (Pubitemid 46745373)
8. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813-824. (Pubitemid 47241890)
9. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-548. (Pubitemid 40563179)
10. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56:739-745. (Pubitemid 46348742)
11. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27: 111-122. (Pubitemid 47089023)
12. Isogawa M, Furuichi Y, Chisari FV. Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity. 2005;23:53-63. (Pubitemid 41019657)
13. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458:206-210.
14. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687. (Pubitemid 43237609)
15. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089-1096. (Pubitemid 40216472)
16. Geng H, Zhang GM, Xiao H, et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer. 2006;118:2657-2664. (Pubitemid 43673341)
17. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14:3044-3051.
18. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-3175.
19. Nam HJ, Song MY, Choi DH, et al. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. Eur J Immunol. 2009;40: 351-358.
20. Ha SJ, Jeon BY, Kim SC, et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Ther. 2003;10:1592-1599.
21. Jin HT, Youn JI, Kim HJ, et al. Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Hum Gene Ther. 2005;16:328-338.
22. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 2000;60:1035-1042.
23. + T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65-78. (Pubitemid 37324571)
24. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92. (Pubitemid 29096240)
25. Wahl C, Bochtler P, Chen L, et al. B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses. Gastroenterology. 2008;135:980-988.
26. + T cells are restricted by the up-regulation of PD-1. J Immunol. 2009;182:4244-4254.
27. Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945-954. (Pubitemid 38924267)
28. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543-9553. (Pubitemid 41507854)
29. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198-1202. (Pubitemid 44527357)
30. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006;203:2281-2292. (Pubitemid 44498363)
31. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350-354. (Pubitemid 44435155)
32. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765-772. (Pubitemid 26148299)
33. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
34. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116-126. (Pubitemid 37323235)
35. Sharpe AH, Abbas AK. T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med. 2006;355:973-975. (Pubitemid 44343539)
36. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005; 105: 13-21. (Pubitemid 40053057)
37. Butte MJ, Pena-Cruz V, Kim MJ, et al. Interaction of human PD-L1 and B7-1. Mol Immunol. 2008;45:3567-3572.
38. Kuipers H, Muskens F, Willart M, et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol. 2006;36:2472-2482. (Pubitemid 44420603)
39. Wang X, Zhang Z, Zhang S, et al. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur J Immunol. 2008;38:3226-3236.
40. Josien R, Wong BR, Li HL, et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol. 1999;162:2562-2568. (Pubitemid 29309274)
41. Min L, Mohammad Isa SA, Shuai W, et al. Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J Immunol. 2010;184:4625-4629.
42. Ruedl C, Kopf M, Bachmann MF. CD8(+) T cells mediate CD40-independent maturation of dendritic cells in vivo. J Exp Med. 1999;189:1875-1884.
43. Armengol G, Ruiz LM, Orduz S. The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response. Mol Biotechnol. 2004;27:109-118. (Pubitemid 41490596)
44. Stone GW, Barzee S, Snarsky V, et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol. 2006;80: 1762-1772. (Pubitemid 43228717)